Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00268333
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : February 9, 2009
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) together with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with radiation therapy works in treating patients with recurrent metastatic colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: fluorouracil Drug: leucovorin calcium Drug: oxaliplatin Procedure: neoadjuvant therapy Phase 2

Detailed Description:



  • Determine the response rate in patients with recurrent metastatic colorectal cancer treated with neoadjuvant oxaliplatin, fluorouracil, and leucovorin calcium followed by radiotherapy and concurrent fluorouracil and oxaliplatin.


  • Determine the overall survival and disease-free survival of patients treated with this regimen.
  • Determine the primary site of recurrence and time to recurrence in patients treated with this regimen.
  • Determine quality of life of patients treated with this regimen.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

  • Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Two to 5 weeks later, patients with stable or responding disease proceed to chemoradiotherapy.
  • Chemoradiotherapy: Patients receive fluorouracil IV continuously 5 days a week for 5 weeks and oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29. Patients also undergo radiotherapy 5 days a week for 5 weeks beginning on day 1.

Quality of life is assessed at baseline, 1 week after the completion of neoadjuvant chemotherapy, on days 15, 30, and 42 of chemoradiotherapy, and at 1 and 2 months after the completion of study treatment.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin
Study Start Date : August 2005
Actual Primary Completion Date : January 2006

Primary Outcome Measures :
  1. Response rate

Secondary Outcome Measures :
  1. Overall survival
  2. Disease-free survival
  3. Primary site of recurrence
  4. Time to recurrence
  5. Quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the colon or rectum

    • Metastatic disease isolated to the following lymph nodes:

      • Aortic
      • Interaortic
      • Celiomesenteric
      • Retroperitoneal, including the following sites:

        • Peri-uretal
        • Liver
        • Iliac
        • Clavicle
        • Mediastinum
        • Inguinal
        • Cervical
  • Incompletely resected disease
  • Recurrent disease, defined by 1 of the following criteria:

    • Progression occurred within 6 months after prior oxaliplatin or after the patient received no prior oxaliplatin
    • Progressive disease after cisplatin or fluorouracil
  • Must be able to be encompassed in radiation field


  • ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
  • Life expectancy more than 12 weeks
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000 /mm^3
  • Alkaline phosphatase ≤ 5 times normal
  • Bilirubin ≤ 2 times normal
  • Creatinine < 2 times normal or creatinine clearance ≥ 40 mL/min
  • No peripheral neuropathy > grade 1
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No weight loss > 15% since diagnosis of recurrent disease
  • No uncontrolled heart disease
  • No angina
  • No symptomatic disease of the inferior artery
  • No psychological, familial, sociological, or geographical condition that would preclude study treatment or compliance


  • See Disease Characteristics
  • No prior chemotherapy or radiotherapy
  • No concurrent corticosteroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00268333

Layout table for location information
Institut Sainte Catherine
Avignon, France, 84082
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France, 25030
Hopital Drevon
Dijon, France, 21000
Hopital Robert Boulin
Libourne, France, 33500
Polyclinique des Quatre Pavillons
Lormont, France, 33310
Hopital Europeen Georges Pompidou
Paris, France, 75015
Hopital Tenon
Paris, France, 75970
Polyclinique De Courlancy
Reims, France, F-51100
C.H. Senlis
Senlis, France, 60309
Sponsors and Collaborators
GERCOR - Multidisciplinary Oncology Cooperative Group
Layout table for investigator information
Study Chair: Laurent Mineur, MD Institut Sainte Catherine
Layout table for additonal information Identifier: NCT00268333    
Other Study ID Numbers: CDR0000453784
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: February 9, 2009
Last Verified: May 2007
Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the colon
adenocarcinoma of the rectum
stage IV colon cancer
stage III colon cancer
stage III rectal cancer
stage IV rectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Protective Agents
Vitamin B Complex